Printer Friendly

IDEC PHARMACEUTICALS RECEIVES NOTICE OF U.S. PATENT ALLOWANCE FOR PANEL OF ANTIBODIES TO TREAT LYMPHOMA

 LA JOLLA and MOUNTAIN VIEW, Calif., Dec. 17 /PRNewswire/ -- IDEC Pharmaceuticals Corporation (NASDAQ: IDPH) has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering its SPECIFID(TM) panel of antibodies for the treatment of non-Hodgkin's B-cell lymphomas and leukemias. The patent is expected to issue in 1993 and is entitled "Anti-Idiotype Antibodies Reactive With Shared Idiotypes Expressed by Human Lymphomas and Autoantibodies."
 Researchers originally believed that the use of anti-idiotype antibodies against lymphomas would require a customized approach to therapy because each patient's lymphomas cells have a unique cell- surface marker known as an "idiotype." However, IDEC Pharmaceuticals discovered that select anti-idiotype antibodies to lymphoma cells are capable of reacting with lymphatic tumors from more than one patient, allowing the possibility for off-the-shelf therapy. Collectively, a panel of such anti-idiotype antibodies represents a potential medical treatment for a significant population of lymphoma patients. The claims of the allowed patent cover panels of these antibodies as well as methods of immunotherapy using such antibodies.
 IDEC Pharmaceuticals is currently conducting human clinical studies at medical centers in the United States and Canada using its SPECIFID panel of anti-idiotype antibodies for the treatment of low- grade and certain types of intermediate-grade non-Hodgkin's B-cell lymphomas. The SPECIFID panel under study contains 15 cross-reactive antibodies that have been manufactured by IDEC's European partner, Boehringer Ingelheim. The objective of the study is to demonstrate the safety of these antibodies and their equivalence to IDEC- manufactured antibodies used in earlier studies. Upon completion of these investigations, IDEC Pharmaceuticals hopes to initiate pivotal clinical studies which would form the primary basis for the filing of a Product License Application with the U.S. Food and Drug Administration for the marketing of the SPECIFID panel.
 IDEC Pharmaceuticals is a leader in the development of immunologically active antibodies for therapeutic applications. These agents are designed to act through immune system mechanisms and potentially offer greater specificity of action, longer therapeutic effect and lower toxicity than is typical of existing therapies. Several human clinical studies are in progress using product candidates for the treatment of immune system cancers (lymphomas and leukemias), malignant melanoma and HIV infection. Late-stage preclinical testing also is under way using additional therapeutic agents for autoimmune diseases and cancer.
 IDEC Pharmaceuticals is headquartered at 11099 North Torrey Pines Road, La Jolla, CA 92037. Company operations are also located in Mountain View, CA.
 -0- 12/17/92
 /CONTACT: Richard W. Krawiec, director, investor relations and corporate communications, 619-458-0600, or Clifford Orent, senior VP and COO, 415-940-1200, both of IDEC Pharmaceuticals/
 (IDPH)


CO: IDEC Pharmaceuticals Corp. ST: California IN: MTC SU:

JB-JL -- SD001 -- 8036 12/17/92 08:30 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 17, 1992
Words:448
Previous Article:TRAINING NEW HIRES COSTS FIVE TIMES MORE; DOWNSIZING REMOVED THE TRAINERS, EXPERT SAYS
Next Article:AMERICAN RESIDENTIAL MORTGAGE CORP. ADDS FIVE NEW OFFICES TO NATIONAL BRANCH NETWORK
Topics:


Related Articles
LA JOLLA PHARMACEUTICAL'S PATENT ALLOWED
IDEC PHARMACEUTICALS RECEIVES NOTICE OF U.S. PATENT ALLOWANCE FOR MELIMMUNE(TM)-2 CANCER VACCINE: THERAPEUTIC TO TREAT MELANOMA
IDEC PHARMACEUTICALS TO RECEIVE U.S. PATENT COVERING PRIMATIZED ANTIBODY TECHNOLOGY
IDEC Pharmaceuticals Receives Notice Of Allowance On Additional Patents Covering PRIMATIZED Antibody Technology

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters